Targeted Alpha-Therapy Market 2026 gaining traction with precision oncology

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Targeted Alpha-Therapy Market In 2026 And What Value Is Projected For 2030?

The targeted alpha-therapy market size has experienced significant growth recently. It is projected to expand from $1.03 billion in 2025 to $1.2 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.2%. The expansion observed in prior periods is attributable to advancements in nuclear medicine research, growing unmet needs in advanced cancer treatment, an increase in radiopharmaceutical clinical trials, the availability of medical isotopes, and the rising adoption of targeted radiation therapy.

The targeted alpha-therapy market size is poised for rapid expansion in the coming years, with projections indicating it will reach $2.25 billion by 2030, advancing at a compound annual growth rate (CAGR) of 17.0%. This upward trajectory during the forecast period can be attributed to several factors, including increased investment in isotope manufacturing infrastructure, the rising embrace of personalized radiotherapy, the broadening of targeted alpha therapies into new indications, growing regulatory backing for radiopharmaceuticals, and enhanced cooperation between nuclear and oncology specialists. Furthermore, key trends anticipated in this period encompass the escalating development of alpha-emitting radiopharmaceuticals, a surge in the use of targeted radioligand therapies, an intensified focus on precision radiation delivery, the expansion of isotope production capabilities, and improved integration of targeting molecules.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28337&type=smp

What Key Drivers Are Influencing The Growth Of The Targeted Alpha-Therapy Market?

The increasing emphasis on precision medicine is projected to stimulate the growth of the targeted alpha-therapy market moving forward. Precision medicine represents a healthcare approach that customizes prevention, diagnosis, and treatment based on an individual’s unique genetic profile, lifestyle, and environment to achieve more effective health outcomes. The rise of precision medicine is attributed to the expanding availability of genetic testing, which enables more accurate diagnoses and specifically targeted treatments, thereby enhancing patient results. Targeted alpha-therapy plays a crucial role in precision medicine by directly delivering highly potent alpha-emitting isotopes to cancer cells, ensuring personalized and precise treatment while minimizing damage to healthy tissues. As an example, the American Pharmaceutical Review, a US-based journal company, reported in March 2024 that global spending on precision medicine treatments was nearly $32 billion in 2022 and is expected to exceed $124 billion by 2027. Thus, the heightened focus on precision medicine is a primary driver for the growth of the targeted alpha-therapy market.

What Are The Key Segments Of The Targeted Alpha-Therapy Market?

The targeted alpha-therapy market covered in this report is segmented –

1) By Isotope Type: Actinium-225, Radium-223, Lead-212, Bismuth-213, Other Isotype Types

2) By Application: Prostate Cancer, Bone Metastases, Pancreatic Cancer, Other Applications

3) By End-User: Hospitals, Cancer Research Institutes, Specialty Clinics, Lymphoma, Other End Users

Subsegments:

1) By Actinium-225: Ac-225 Lintuzumab, Ac-225 PSMA-617, Ac-225 DOTATATE

2) By Radium-223: Radium-223 Dichloride (Xofigo)

3) By Lead-212: Pb-212 DOTAMTATE (AlphaMedix), Pb-212 TCMC-Trastuzumab

4) By Bismuth-213: Bi-213 Lintuzumab, Bi-213 DOTATOC

5) By Other Isotope Types: Thorium-227, Astatine-211, Terbium-149

What Key Trends Are Influencing The Development Of The Targeted Alpha-Therapy Market?

Leading companies in the targeted alpha-therapy market are concentrating on developing innovative solutions, such as peptide receptor radionuclide therapy, to enhance the effectiveness of targeted cancer treatment, reduce unwanted side effects, and improve patient outcomes. Peptide receptor radionuclide therapy (PRRT) is a targeted cancer treatment that delivers radioactive isotopes directly to tumor cells by attaching them to peptides that specifically bind to receptors overexpressed on cancer cells, thereby minimizing damage to healthy tissue. For instance, in February 2024, RadioMedix Inc., a US-based biotechnology company, partnered with Orano Med, a US-based pharma company, and their product, AlphaMedix (lead-212-Dotamtate), aimed at treating neuroendocrine tumors, became the first targeted alpha therapy to receive FDA breakthrough device designation. It is designed to treat advanced gastroenteropancreatic neuroendocrine tumors by directly delivering highly potent alpha radiation to cancer cells while sparing healthy tissue. Its primary advantage is rooted in the high energy and short path length of alpha particles, which cause lethal DNA damage to tumor cells with minimal toxicity. This therapy presents a promising option for patients who are new to or have shown limited response to current beta-emitter treatments, with the goal of improving efficacy and safety in hard-to-treat neuroendocrine tumors.

Who Are The Leading Companies Operating In The Targeted Alpha-Therapy Market?

Major companies operating in the targeted alpha-therapy market are Bayer Aktiengesellschaft, Novartis AG, Lantheus Holdings Inc., Telix Pharmaceuticals Limited, Eckert & Ziegler Strahlen- und Medizintechnik AG, Actinium Pharmaceuticals Inc., RayzeBio Inc., ITM Isotope Technologies Munich SE, ARTBIO Inc., AdvanCell Pty Ltd., IONETIX Corporation, Abdera Therapeutics Inc., Aktis Oncology Inc., Alpha-9 Oncology Inc., Clarity Pharmaceuticals Pty Ltd., Nucleus RadioPharma, Oncoinvent AS, PanTera, Perspective Therapeutics Inc., RadioMedix Inc.

Read the full targeted alpha-therapy market report here:

https://www.thebusinessresearchcompany.com/report/targeted-alpha-therapy-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Targeted Alpha-Therapy Market?

North America was the largest region in the targeted alpha-therapy market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the targeted alpha-therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Targeted Alpha-Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28337&type=smp

Browse Through More Reports Similar to the Global Targeted Alpha-Therapy Market 2026, By The Business Research Company

Targeted Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

Alpha Hydroxy Acid Market Report 2026

https://www.thebusinessresearchcompany.com/report/alpha-hydroxy-acid-global-market-report

Alpha 1 Antitrypsin Deficiency Augmentation Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795